22:46:52 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-23 Kvartalsrapport 2024-Q1
2024-03-22 Ordinarie utdelning CURAS 0.00 DKK
2024-03-21 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-03-31 Ordinarie utdelning CURAS 0.00 DKK
2023-03-30 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-27 Årsstämma 2022
2022-03-25 Ordinarie utdelning CURAS 0.00 DKK
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-06-01 Extra Bolagsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-03-26 Ordinarie utdelning CURAS 0.00 DKK
2021-03-25 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-11-30 Kvartalsrapport 2020-Q3

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriMedicinteknik
Curasight är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av teknologiska produkter. Produktportföljen är bred och har sin huvudsakliga fokus på utveckling av produkter inom området Positron Emissions Tomography (PET). Verksamheten drivs med störst närvaro inom Skandinavien. Curasight har sitt huvudkontor i Köpenhamn.
2022-02-24 07:00:00

Curasight A/S ("Curasight" or "the Company") hereby publishes the Year-end report for the period October 1 - December 31, 2021. The Year-end report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

Curasight's CEO Ulrich Krasilnikoff comments:

"As we close the books for the financial year 2021, we can look back on an eventful year in Curasight's history. In 2021 we have accomplished several important milestones including strengthening Curasight's IP position within diagnostics and therapy with patent approvals in both US and Canada. We have also seen promising results during the year from several academic investigator-initiated phase II studies regarding indications in prostate, head and neck cancer and most recently in neuroendocrine tumors (NET). I want to thank everyone who exercised their warrants of series T0 1, in the exercise period that ran from September to October 2021, for the confidence shown in Curasight and our technology. Curasight is now in a strong financial position, and we will focus on accelerating our ongoing programs within brain and prostate cancer to deliver on our ultimate goal - improving the lives of millions of cancer patients.

2022 is set up to be even more eventful than 2021 with the highlights that lie ahead as we expand our clinical portfolio with two additional cancer indications in head and neck cancer and neuroendocrine tumors (NET), besides prepare all four indications for the pivotal phase III studies and the process towards approval. This will be communicated in near future in connection with the updated strategy."

Fourth quarter 2021
  • Net sales amounted to 0 (0) DKK
  • Operating profit/loss amounted to -4,630,649 (-4,425,970) DKK
  • Profit/loss before taxes amounted to -5,257,338 (-4,767,110) DKK
  • Profit/loss for the year amounted to -4,852,432 (-4,767,178) DKK
  • Total assets amounted to 102,614,298 (63,105,845) DKK
  • Equity ratio amounted to 96.6 (93.7)
  • Earnings per share amounted to -0.24 (-0.27)
January - December 2021
  • Net sales amounted to 0 (0) DKK
  • Operating profit/loss amounted to -6,210,420 (-4,791,150) DKK
  • Profit/loss before taxes amounted to -8,752,515 (-5,773,575) DKK
  • Profit/loss for the year amounted to -7,578,670 (-5,552,201) DKK
  • Total assets amounted to 102,612,298 (63,105,845) DKK
  • Equity ratio amounted to 96.6 (93.7)
  • Earnings per share amounted to -0.38 (-0.32)
Highlights during the fourth quarter
  • On October 7, the exercise period for Curasight's warrants of series TO 1 ended. A total of 2,767,551 warrants of series TO 1 were exercised. Curasight received a total of approximately DKK 47.6 million before issue costs.
  • On December 9, Curasight announced that results from an investigator-initiated phase II study performed by researchers at Rigshospitalet using the uTRACE® technology demonstrated prognostic value of uPAR-PET in head and neck cancer patients.
  • On December 14, Curasight announced that a transaction with shares in Curasight A/S was made by managerial employee. Kirsten Drejer, who is a member of the Board of directors, purchased 3,886 shares a price of 123,058.35 DKK in total. Kirsten Drejers total holdings in Curasight A/S after the purchase of the shares is 3,886 shares.
  • On December 21, Curasight announced that Company appoints Hanne Damgaard Jensen as new Chief Development Officer starting from 1 January 2022. Hanne will be responsible for all Drug Development and Regulatory Affairs activities in the Company.
Highlights after the period
  • On January 10, Ulrich Krasilnikoff and Andreas Kjær were invited and attended J.P. Morgan 40th Healthcare Conference.
  • On January 27, Curasight announced that results from an investigator-initiated phase II study performed by researchers at Rigshospitalet using the uTRACE® technology in neuroendocrine tumor patients demonstrate strong prognostic value and supports potential future use of uPAR-targeted radionuclide therapy.
  • On February 10, Curasight announced that the Company has signed and completed an agreement to acquire the early-stage R&D company TRT Innovations ApS. Curasight intends to expand and accelerate its clinical programs and is strengthening the therapeutic platform.